Genetic Tech Ltd.-SP ADRGENE
13F holders, Q2 2024 (June 30)7holders +1
2new positions
1sold out
$1.50avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Genetic Tech Ltd.-SP ADR (GENE) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($210K), Susquehanna International Group, LLP ($115K) and Morgan Stanley ($27K).
- Company
- Genetic Tech Ltd.-SP ADR
- CUSIP
- 37185R406
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $210K |
| Exits | 1 | $633 |
All 13F filers, Q1 2024 → Q2 2024: 186,962 shares bought and 219 shares sold, net +186,743 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Armistice Capital, LLC | 0.01% | New | 140,000 | $210K |
| Susquehanna International Group, LLP | 0.00% | Add +123.4% | 77,303 | $115K |
| Morgan Stanley | 0.00% | Add +2.9% | 17,989 | $27K |
| BNP Paribas Financial Markets | 0.00% | Add +38.5% | 12,600 | $19K |
| Rhumbline Advisers | 0.00% | No change | 3,739 | $6K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 400 | $600 |
| Simplex Trading, LLC | 0.00% | New | 255 | $0 |
"% of holder's portfolio" is GENE's weight in each manager's 13F, not the share of Genetic Tech Ltd.-SP ADR the manager owns.